Black Rose FY26: Manufacturing strength lifts margins despite softer revenue

Black Rose Industries Limited used its FY2025-26 earnings webinar to show a familiar pattern for chemical businesses in a correcting price cycle: revenue can move down even when operating performance improves. On a standalone basis, revenue from operations for FY26 came in at INR 3,258.38 million versus INR 3,406.85 million in FY25, a 4.36 percent decline. Yet EBITDA rose 8.27 percent to INR 354.33 million, and profit after tax increased 7.34 percent to INR 224.96 million. The numbers point to better mix, tighter cost control, and a manufacturing segment that did more heavy lifting this year.

The quarterly exit rate also mattered. In Q4 FY26, standalone revenue rose sharply to INR 1,047.79 million from INR 758.62 million in Q3 FY26, while EBITDA nearly doubled to INR 137.62 million from INR 72.33 million. PAT for the quarter came in at INR 94.16 million versus INR 44.08 million in the prior quarter. For investors, this Q4 bounce is not just a seasonality footnote. It frames how the company managed through a year where chemical prices corrected and export conditions were mixed.

A two-engine model, with manufacturing taking the lead

Black Rose operates with a clear split between chemical distribution and chemical manufacturing, supported by a specialty chemicals footprint that includes acrylamide liquid capacity of 32,000 MTPA (20,000 MTPA for merchant sales and 12,000 MTPA for captive requirement), acrylamide solid capacity of 3,600 MTPA, and N-methylol acrylamide capacity of 2,000 MTPA. The company also referenced polyacrylamide solid capacity of 10,000 MTPA as being in R and D. Legacy businesses such as industrial fabrics and made-ups in Kolhapur and two windmills in Gujarat and Rajasthan remain present but contribute less than 1 percent of revenue.

FY26 was shaped by a divergence between the two core segments. Distribution volumes grew on domestic demand, but reported revenue fell because of price decline. Manufacturing, on the other hand, expanded volumes for acrylamide liquid and NMA, improved cost efficiency, and benefited from new customer additions and export focus.

Standalone segment disclosure (in crores) makes the shift visible. Distribution delivered revenue of INR 209.12 crore with EBITDA of INR 17.25 crore. Manufacturing delivered revenue of INR 114.10 crore with EBITDA of INR 25.06 crore. Total standalone EBITDA for the year was INR 35.43 crore, with unallocated items of negative INR 6.88 crore.

FY26 financial performance: lower sales, higher profitability

The year ended with stronger margins. Standalone EBITDA margin improved to 11.0 percent in FY26 from 9.7 percent in FY25. PAT margin also improved to 7.0 percent from 6.3 percent. EPS increased to INR 4.41 from INR 4.11. At the balance sheet level, the company reduced leverage meaningfully, with total debt to equity declining to 0.01x from 0.06x.

A notable detail is the steep reduction in loans. Standalone loans fell to INR 1.5 million at FY26 year-end from INR 90.0 million in FY25. Net worth rose to INR 1,692.8 million from INR 1,526.5 million, reflecting profit accretion. The company also carried INR 200.1 million in current investments in both FY25 and FY26.

Working capital moved in a way that suggests normalization after a heavier inventory position in FY25. Inventories declined to INR 479.9 million from INR 714.7 million. Other current assets reduced sharply to INR 55.5 million from INR 168.1 million. Trade receivables increased to INR 696.1 million from INR 665.5 million, while trade payables fell to INR 250.6 million from INR 396.5 million. Cash and bank balances improved to INR 97.3 million from INR 75.2 million.

Distribution: volumes up, prices down, and exports under pressure

Distribution remains the larger revenue contributor, but FY26 showed how sensitive this business is to price and trade conditions. Total distribution revenue fell to INR 2,091 million in FY26 from INR 2,431 million in FY25. Distribution EBITDA declined to INR 173 million from INR 210 million.

Management commentary pointed to domestic volume growth, but a price decline that pulled the top line lower. The company also noted that a stock-and-sales model supported Q4 growth amid the Middle East crisis, suggesting Black Rose leaned into availability and execution when supply conditions were stressed. On the export side, merchant exports were described as weak due to U.S. tariffs, which is important context because it separates demand weakness from policy-driven friction.

Concentration remains a monitoring point. The top five products contributed 73 percent of distribution revenue and 76 percent of distribution profits. This can be a strength if the products are sticky and well-positioned, but it also means changes in a small set of product dynamics can swing results.

Manufacturing: stronger mix and operating discipline

Manufacturing was the more positive story in FY26. Total manufacturing revenue increased to INR 1,141 million from INR 948 million in FY25. EBITDA rose sharply to INR 251 million from INR 172 million. This is the key reason consolidated and standalone margins expanded even as total revenue softened.

The company attributed the improvement to higher volumes in acrylamide liquid and NMA, new customer additions, and focus on exports. It also highlighted cost efficiency as a margin driver. Acrylamide solid volumes were described as stable. Another relevant decision was a strategic exit from the Morbi ceramic binder business, which indicates management is willing to prune activities that do not fit return goals or risk appetite.

The revenue mix between manufacturing and distribution shifted in FY26. Manufacturing increased its share while distribution reduced its share, and the company also shared export versus local mix. Exports were 15 percent in FY26 versus 24 percent in FY25, while local sales were 85 percent versus 77 percent. The change suggests that FY26 growth leaned more on domestic execution at a time when external trade conditions were less supportive.

Pricing signals: acrylonitrile and acrylamide volatility matters

The webinar included a price trend for April 2025 to March 2026 covering acrylonitrile (ACN) and acrylamide liquid pricing. The stated data shows acrylamide liquid naked price in rupees per kg moving down through much of the year from 1134 in April 2025 to 996 in November 2025, before turning higher to 1103 in January 2026 and spiking to 1350 in March 2026.

ACN prices also moved sharply in March 2026. IHS ACN was shown rising to 1510 dollars per metric ton in March 2026 from 1116 in February 2026, while the ICIS ACN line moved to 63 in March 2026 from 56 in February 2026. For a manufacturer with acrylamide exposure, this type of movement can affect spreads, purchasing behavior, and customer negotiations. It also explains why quarterly performance can swing even when annual volumes are steady.

Capital structure and returns: balance sheet flexibility improves

The balance sheet signals are consistent with the margin story. The company improved return on capital employed to 18.24 percent in FY26 from 17.89 percent in FY25. Return on equity eased to 13.29 percent from 13.90 percent, but that decline sits alongside higher net worth and lower leverage, so it is not necessarily a sign of weaker operations.

A key positive is the very low debt level at year-end. With total debt to equity at 0.01x and loans at INR 1.5 million, the company has room to pursue projects without forcing balance sheet risk. This matters because the manufacturing roadmap includes development work that can require time and iteration before it becomes scale-ready.

What management is guiding for Q1 and beyond

For the current quarter outlook, the company kept its tone practical. In distribution, it plans to add new products and expand the end-user customer base. It expects higher prices to support overall revenue, while also warning that near-term demand may remain subdued in Q1 due to global uncertainties. It expects merchant export volumes to rise on the back of a strong order pipeline.

For manufacturing, the company expects domestic demand for acrylamide to pick up in the second half. It aims to focus on acrylamide liquid exports to key accounts and expects acrylamide solid volumes to remain steady. For NMA, the outlook is stable with continued focus on new customer additions.

On projects, management said the PAM solid project has advanced to piloting, and new downstream acrylamide products are under development. A specialty amines project decision is expected during the year. The through-line is portfolio diversification within a familiar chemistry adjacency, while keeping an eye on execution readiness.

Investor takeaways: disciplined execution in a correcting cycle

FY26 for Black Rose reads like a year of operational discipline rather than headline growth. Total revenue declined, but EBITDA and PAT increased, and margins expanded. That is the result investors typically look for when a commodity-linked price cycle is working against reported sales.

The split between distribution and manufacturing is also becoming more meaningful. Distribution remains the larger business, but manufacturing delivered higher EBITDA in FY26 and provided stability when pricing and exports pressured distribution revenue. Management actions, including the exit from the Morbi ceramic binder business and a focus on cost efficiency, signal attention to quality of earnings.

The near-term outlook has two moving parts that investors should track closely: how quickly demand and pricing normalize in distribution, and whether manufacturing can sustain improved profitability as input and output prices move. With leverage low and projects like PAM solid moving into piloting, the company has room to invest, but the next phase will depend on how effectively it converts development work into scalable, profitable product lines.

In summary, the FY26 theme is clear: margin-led performance supported by manufacturing execution and balance sheet strengthening. If the company can pair that with a steadier export environment and successful product additions in distribution, the next set of results may show not just better profitability, but a more resilient earnings profile across cycles.